Action International for Health (AIS) Peru is an organization dedicated to promoting universal access to medicines, vaccines, and other essential health technologies as fundamental components of the right to health. Its work focuses on defending public policies that ensure the availability, accessibility, and rational use of these products, especially in contexts of social and economic vulnerability.
Trastuzumab in Peru: current situation and prospects
Home/Reports
|
Posted 16/01/2026
0
Post your comment
The report ‘Trastuzumab in Peru: A Renewed Monopoly’, published in October 2025 by AIS Peru, analyses the situation of trastuzumab, an essential biotech drug for treating of HER2-positive breast cancer.
Following the entry of biosimilars into the market, the price of intravenous trastuzumab fell significantly, reaching a 94% reduction by 2024. However, Roche has obtained patents for a new 600 mg subcutaneous formulation, valid until 2030, which could reestablish a monopoly and increase treatment costs.
The report highlights the need to strengthen competition policies and rigorously evaluate patent applications to avoid unjustified exclusivity that restricts access to health technologies and, consequently, undermines the right to health.
Related articles
DIGEMID’s 45-day auto-approvals trigger safety warning
Access to biosimilars for cancer treatments in Latin America
Biosimilar regulations perspective in Latin America to improve cancer treatment access
|
LATIN AMERICAN FORUM View the latest headline article: Directriz estadounidense para eliminar los estudios comparativos de eficacia de los biosimilares Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.
FORO LATINOAMERICANO Ver el último artículo de cabecera: Directriz estadounidense para eliminar los estudios comparativos de eficacia de los biosimilares !Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. |
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2026 Pro Pharma Communications International. All Rights Reserved.
Guidelines
US guidance to remove biosimilar comparative efficacy studies
New guidance for biologicals in Pakistan and Hong Kong’s independent drug regulatory authority
Policies & Legislation
WHO to remove animal tests and establish 17 reference standards for biologicals
Related content
EU steps closer to the ‘tailored approach’ for biosimilars development
Home/Reports Posted 21/11/2025
Advancing biologicals regulation in Argentina: from registration to global harmonization
Home/Reports Posted 10/10/2025
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment